Octopus Ventures

Not financial or fundraising advice. See full disclaimer.

Tickets

£25K - £100K
£100K - £500K
£500K - £2M
£2M - £10M
£10M - £30M

Rounds

Pre-Seed
Seed
Pre-Series A
Series A
Later Rounds

Sectors

B2B Software
Biotech
Climate / Green
Consumer
Deep Tech
Fintech
Health

Target Geography

United Kingdom
Europe

Last Edited:

October 2, 2025

To suggest a correction to the database, or request to be added or removed from it, contact us at info@adeline.co.uk.

Octopus Ventures has quietly become one of Europe’s most influential venture capital players, backing startups from early ideas through to billion-dollar exits. Founded in 2008 and headquartered in London—with an additional base in New York—Octopus manages approximately £2 billion, investing predominantly in seed and Series A-stage companies, and increasingly at the pre-seed level.

The firm has cultivated a reputation as a long-term partner, distinguished not merely by the size of its chequebook, but by its distinctly people-centric philosophy. Its motto—“venture capital for the founders building a better tomorrow”—is more than marketing fluff. Octopus consistently prioritises investments that promise significant social or environmental impact, making it particularly appealing to founders whose startups are driven by mission as much as profit. Its certified B Corp status further underscores this commitment.

While sector-agnostic in practice, Octopus Ventures leans into specialist expertise across seven distinct areas: B2B software, biotech and healthtech, climate, consumer, deep tech, fintech, and broader healthcare. Notable alumni include household names like Zoopla, Graze, and Depop—the latter of which sold to Etsy in a $1.6 billion deal in 2021.

Founders approaching Octopus can expect a relatively streamlined process, with initial decisions at seed-stage typically made within four weeks. Pre-seed founders, particularly those with compelling visions and strong founding teams, might receive a term sheet within two weeks. However, speed does not diminish thoroughness: Octopus rigorously assesses unit economics, early market traction, and above all, the calibre of the founding team.

Rather than a passive cash injection, founders find themselves supported by a six-person People & Talent team dedicated entirely to helping them scale. Octopus even mandates founder engagement with executive coaching—a rare but positively received requirement designed to build resilience and enhance leadership capacity.

Alex Saint, CEO of Secret Escapes, described Octopus Ventures as genuine partners, saying that its support meant, “we were able to keep the momentum going throughout the funding process. The long-term relationships we have built with the team at Octopus over the last four years has played a crucial role in Secret Escapes’ own development.”

Yet, for all its hands-on involvement, Octopus is known for respecting founder autonomy, preferring supportive collaboration over intrusive interference. Its approachability and humility stand out in a venture landscape often criticised for heavy-handedness.

For UK-based founders with big ideas, particularly those solving meaningful problems, Octopus Ventures offers not only capital but a robust ecosystem designed to nurture both businesses and the people building them.

Pitch Adeline Arts & Science

Adeline is a London-based family office investing in pre-seed, seed and series A startups.

£25K - £100K
£100K - £500K
£500K - £2M
£2M - £10M
£10M - £30M
Pre-Seed
Seed
Pre-Series A
Series A
Later Rounds
B2B Software
Biotech
Climate / Green
Consumer
Deep Tech
Fintech
Health
United Kingdom
Europe

The AI operating system for private capital: why we invested in Capsa AI

Adeline Arts & Science has backed Capsa AI, joining their $18 million Series A co-led by TX Ventures and Pivot Investment Partners. Capsa turns a private capital firm's accumulated deal history and institutional knowledge into a live intelligence layer, surfacing insights and automating the critical workflows that matter most for investment teams.

Read More
Arrow pointing right

Preventing Hospital Outbreaks with Predictive AI: Why Adeline is backing NEX Health Intelligence

Adeline Arts and Science has backed NEX Health Intelligence, joining their €1 million pre-seed round alongside lead investor Brighteye Ventures and a syndicate of early backers. NEX is building the Infection Intelligence Platform for modern hospitals — a system that moves infection prevention from reactive surveillance to predictive action.

Read More
Arrow pointing right